Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Articles online first > Minerva Pediatrica 2019 Jun 28

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Pediatrica 2019 Jun 28

DOI: 10.23736/S0026-4946.19.05544-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

The relation between activator and inhibitor killer-cell immunoglobulin-like receptors (KIRs) and hepatotoxicity in oncological treatment

Emilia URRUTIA-MALDONADO 1, María ALÉS-PALMER 2, Paloma MUÑOZ DE RUEDA 3, Irene PELÁEZ-PLEGUEZUELOS 4, Esther OCETE-HITA 1

1 Hospital Materno Infantil Virgen de las Nieves, UGC Médico Quirúrgica de la INFANCIA, Servicio de Oncología Pediátrica, Granada, Spain; 2 Hospital Rafael Méndez, Lorca España, Servicio de Pediatría, Lorca, Spain; 3 Instituto Biosanitario de Granada, Hospital Universitario San Cecilio, Granada, Spain; 4 Servicio de Pediatria, Hospital Universitario de Jáen, Jáen, Spain; 5 Materno Infantil Virgen de las Nieves, UGC Médico Quirúrgica de la Infancia, Universidad de Granada, Ciber-ehd, Granada, Spain


PDF


BACKGROUND: The molecular interactions between killer-cell immunoglobulin-like receptors (KIRs) and their related HLA class I ligands play a central role in regulating the responses of natural killer (NK) cells. Our study aim was to determine the role played by KIR genes and their HLA ligands in the genetic predisposition for the development of hepatotoxicity in children treated with chemotherapy for an oncological process.
METHODS: The study group was composed of 22 children with cancer, being treated with chemotherapy at the Paediatric Oncology Unit of the Virgen de las Nieves University Hospital (Granada, Spain) and presenting signs of drug-induced liver injury (DILI). Twenty-four children receiving similar treatment but presenting no signs of DILI were selected as a control group.
RESULTS: The children with the KIR K2DS2 were four times more likely to have hepatotoxicity (OR = 4.08, P = 0.034, 95% CI = 1.1-15). The patients with 2DS2 and the C1 ligand were ten times more likely to undergo an episode of hepatotoxicity (p = 0.007).
CONCLUSIONS: KIRs may be risk factors for susceptibility to hepatotoxicity following chemotherapy.


KEY WORDS: Hepatotoxicity - Killer-cell inmmunoglobulin like receptors - Drug-induced liver injuri - Chemotherapy

inizio pagina